Compared with placebo, the administration of SGLT2 inhibitors significantly reduced the risk of CV death by 13% (RR 0.87; 95% CI: 0.82–0.93; p for heterogeneity 0.34; I2 = 11%; p < 0.01) (Figure 4), the risk of MACE by 11% (RR 0.89; 95% CI: 0.84–0.94; p for heterogeneity 0.07; I2 = 46%; p < 0.01) (Figure 4), and the risk of HF by 30% (RR 0.70; 95% CI: 0.66–0.74; p for heterogeneity 0.98; I2 = 0%; p < 0.01) (Figure 4). The gene discussed is SLC5A2; the disease is hydrops fetalis.